Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Generics Save Money: St. Marianna Univ. Hospital
March 17, 2008
- Switching Nicotinell TTS to OTC Status Recommended
March 17, 2008
- Eisai Aims at \1.5 Trillion Sales in FY2016
March 17, 2008
- SELF-MEDICATION NEWS IN BRIEF
March 17, 2008
- Kyowa Hakko Licenses KW-8761 to Amgen
March 17, 2008
- Correct Diagnosis of Pompe Disease Is Important: Dr Kawai
March 17, 2008
- Nippon Shinyaku to License NS-304 to Actelion
March 17, 2008
- Molecular-targeted Drugs to Revolutionize the Treatment for Renal Cell Carcinoma: Prof. Akaza
March 17, 2008
- Bendamustine May Become a First-Line Therapy: SymBio
March 17, 2008
- Clexane Added as a New Treatment Option for VTE: sanofi-aventis
March 17, 2008
- Additional Indication for Herceptin to Boost Sales: Chugai
March 17, 2008
- Dr Karasawa Officially Announces His Candidacy
March 17, 2008
- NPhA Announces Policy to Improve Drug Distribution Practices
March 17, 2008
- TOPICS 2 articles
March 17, 2008
- Korosho Hears Major Pharmacy Chain Operators
March 17, 2008
- Quintiles Embarks on HMS Business
March 17, 2008
- Claritin Ranked No. 1 in January in Rep Track Survey
March 17, 2008
- NHI Prices Down 10% for ARBs and SSRIs
March 17, 2008
- PMDA Announces Draft Operation and System Optimization Plan
March 10, 2008
- Range of Public Healthcare Benefits to Become Center of Discussions
March 10, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…